Lillian L. Siu, MD, FRCPC, discusses the background for evaluating first-line petosemtamab plus pembrolizumab in recurrent/metastatic PD-L1+ HNSCC.
Lillian L Siu, MD, FRCPC
Advertisement
Articles by Lillian L Siu, MD, FRCPC
Lillian L Siu, MD, FRCPC, discusses a phase 3 trial of petosemtamab plus pembrolizumab vs pembrolizumab alone for recurrent/metastatic PD-L1+ HNSCC.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on OncLive
1
FDA Accepts BLA for Ivonescimab Plus Chemotherapy in EGFR-Mutant NSCLC After TKI Progression
2
HPV Vaccination and Evolving Screening Strategies Continue to Shape Cervical Cancer Prevention Efforts
3
The OncFive: Top Oncology Articles for the Week of 1/25
4
FDA Approval Sought for Lirafugratinib in Second-Line, FGFR2-Altered Cholangiocarcinoma
5